<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164888</url>
  </required_header>
  <id_info>
    <org_study_id>CIVI 007-02-01</org_study_id>
    <nct_id>NCT04164888</nct_id>
  </id_info>
  <brief_title>Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy</brief_title>
  <official_title>A Placebo-controlled, Randomized, Phase 2a, Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CIVI 007 in Patients on a Background of Stable Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Civi Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Civi Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses&#xD;
      of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of&#xD;
      statin therapy with or without ezetimibe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Actual">November 17, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of CIVI 007 adverse events (AEs)</measure>
    <time_frame>2 month followup</time_frame>
    <description>Incidence of any drug-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of CIVI 007 safety laboratory abnormalities</measure>
    <time_frame>2 month followup</time_frame>
    <description>Incidence of clinically significant safety laboratory abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacodynamic effect of CIVI 007</measure>
    <time_frame>1 month followup</time_frame>
    <description>Percent change from baseline in PCSK9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacodynamic (PD) effect of CIVI 007</measure>
    <time_frame>2 month followup</time_frame>
    <description>Percent change from baseline in PCSK9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the lipid efficacy of CIVI 007</measure>
    <time_frame>1 month followup</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the lipid efficacy of CIVI 007</measure>
    <time_frame>2 month followup</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>CIVI 007, Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIVI 007, Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of PCSK9 inhibitor- dose titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIVI 007, Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of PCSK9 inhibitor- high dose given twice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC injection matching PCSK9 inhibitor given twice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIVI 007</intervention_name>
    <description>hypercholesterolemia agent</description>
    <arm_group_label>CIVI 007, Dose A</arm_group_label>
    <arm_group_label>CIVI 007, Dose B</arm_group_label>
    <arm_group_label>CIVI 007, Dose C</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index (BMI) between 18.0 and 40.0&#xD;
&#xD;
          2. Stable (&gt;4 weeks prior to the Screening Visit) dose of statin therapy with or without&#xD;
             ezetimibe&#xD;
&#xD;
          3. Fasting low-density lipoprotein cholesterol (LDL-C): ≥100 mg/dL for those without&#xD;
             cardiovascular disease, or ≥70 mg/dL for those with cardiovascular disease.&#xD;
&#xD;
          4. Fasting triglycerides (TGs) &lt;400 mg/dL&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant, nursing or breast feeding&#xD;
&#xD;
          2. Currently prescribed a lipid lowering agent other than a statin or ezetimibe.&#xD;
&#xD;
          3. Clinically significant disorder or laboratory abnormality that could contraindicate&#xD;
             the administration of study drug, affect compliance, interfere with study evaluations,&#xD;
             or confound the interpretation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L Shear, DrPH</last_name>
    <role>Study Director</role>
    <affiliation>CiVi Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <zip>44224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <disposition_first_submitted>January 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2021</disposition_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

